Benzinga··Lekha GuptaEli Lilly's $1B Biotech Blitz Signals Aggressive Push Into Infectious Diseases
Eli Lilly announces three biotech acquisitions targeting shingles, drug-resistant bacteria, and EBV vaccines, bolstering infectious disease portfolio amid strong stock momentum.
LLYtechnical analysisacquisitions